Update following 2021 Annual General Meeting

Mediclinic International plc, a diversified international private healthcare services group, refers to the outcome of the voting which took place at its July 2021 annual general meeting ("AGM") in relation to the resolution to authorise the directors to allot ordinary shares (Resolution 18), which received 79.60% support from shareholders.

The Company seeks to maintain regular dialogue with its shareholders to establish an open forum for discussion on key market and Company-specific matters, and values the time shareholders have made available to engage with the Company since the 2021 AGM.

In relation to Resolution 18 to authorise the directors to allot ordinary shares, the board of directors ("Board") notes that the voting outcome reflects the differing market practice between the United Kingdom ("UK") and South Africa, where shareholders in the latter jurisdiction usually approve more restricted levels of authority to issue shares and prefer to vote on the proposed allotments of shares on a case-by-case basis.

Most South African shareholders acknowledge that they operate under policies that do not permit support of the standard UK level of authority to allot ordinary shares, although a number do understand the Company’s position. As Mediclinic is a UK premium-listed company, the Board considers it appropriate to seek authorities in line with the UK’s Investment Association’s Share Capital Management Guidelines to: (a) allow the Company to respond to market developments; and (b) enable allotments to take place to finance business opportunities as they arise. The views of all shareholders are important to Mediclinic and the Board will continue to engage with South African shareholders on this topic, however, as the voting outcome reflects the difficulty in balancing the expectations of different markets, it is possible this outcome continues.

About Mediclinic International plc
Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the UAE.

The Group’s core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.
At 30 September 2021, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health facilities, 19 day case clinics and 20 outpatient clinics. Hirslanden operated 17 hospitals and four day case clinics in Switzerland with around 1,900 inpatient beds; Mediclinic Southern Africa operations included 50 hospitals (three of which in Namibia), five subacute hospitals, two mental health facilities and 13 day case clinics (four of which operated by Intercare) across South Africa, and around 8,600 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 20 outpatient clinics with around 1,000 inpatient beds in the UAE. In addition, under management contracts Mediclinic Middle East operates one hospital in Abu Dhabi and will open a 200-bed hospital in the Kingdom of Saudi Arabia in 2023.

The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United Kingdom, with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.

For further information, please contact:

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Ben Atwell/Ciara Martin – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd